Rui Kuai and Dr. Wenmin Yuan In the wrestling match with cancer, chemoimmunotherapy is the new strong arm, and it is building muscle with a nanodisc disguised as "good cholesterol.
The nanodisc is made of a synthetic version of high density lipoprotein HDLalso known as " good cholesterol. Moon, Ph. In multiple mouse tumor models of colon cancer, researchers found up to 85 percent of the tumors were completely eliminated when combining the nanodisc-delivered chemotherapy with immune checkpoint blockers, a common immunotherapy treatment.
Recommended for you
In a more challenging model of cancer, one that metastasized to the liver, the treatment also showed an excellent response rate of 88 percent. To determine if cells are harmful to the body and need to be attacked, the immune system uses certain molecules called checkpoints.
But some cancer cells avoid an immune system attack by producing proteins that trick the checkpoints. Checkpoint blockers were designed to allow immune cells to kill cancer cells. These immunotherapy treatments are highly successful in some patients, but only about 20 percent will benefit.
Delivering cancer treatment on a nanodisc helps eliminate tumors
By using the synthetic HDL, which mimics natural HDL in the body, the researchers were able to hide the chemotherapy from the immune system. James Moon, Ph.
Received Mar 9; Accepted Apr 8.
Credit: University of Michigan College of Pharmacy "When we attached the chemotherapy rectal cancer radiation therapy side effects to the synthetic HDL, we saw significant improved circulation half-life, improved delivery to the tumor cells and a better accumulation of the drug in the tumor cells," says study co-senior author Anna Schwendeman, Ph.
The immune system was empowered to recognize and attack tumor cells. There were no overt side effects to the new delivery system.
And interestingly, the researchers discovered another unexpected benefit: less impact on the heart. But we found that by delivering doxorubicin on the synthetic HDL nanodisc, we saw better accumulation of the drug in the tumor and we didn't detect any cardiotoxicity," Schwendeman says. That may have contributed to the absence of cardiotoxicity," she adds, noting that more research is needed to confirm that speculation.
Our results demonstrating their efficacy in multiple tumor models suggest that our strategy may have wide applications in multiple cancer types," Moon says. Phase I clinical trials have been conducted for the synthetic HDL nanodisc, which has been determined to be safe, Moon says.
- Laryngeal papilloma speech therapy
- Hormonal cancer breast
- Skin papillomatosis histology
- Hpv virusunun tedavisi nedir
- Verruca foot disease treatment
Next, the researchers are working to test the therapy on humans in clinical trials. Explore further More information: "Elimination of established tumors with nanodisc-based combination chemoimmunotherapy" Science Advances DOI: Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission.
The content is provided for information purposes only.